Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Renhaim personalized neoantigen cancer vaccine
- Development stage
- Preclinical
- Lead developer
- Renhaim
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Renhaim's personalized neoantigen cancer vaccine is an mRNA-based immunotherapy designed to treat various cancers by targeting patient-specific tumor neoantigens. The vaccine utilizes mRNA technology to encode unique mutations (neoantigens) identified from a patient's own tumor through genomic sequencing. Once administered, the mRNA is translated into neoantigenic proteins within the patient's cells, which are then processed and presented to the immune system. This process is intended to provoke a robust and individualized anti-tumor T-cell response, allowing the immune system to recognize and eliminate cancer cells expressing those specific mutations. The program is currently in the preclinical/research stage of development.
- Other names
- Personalized Neoantigen Cancer VaccineRenhaim-patient-specific tumor neoantigens-mRNA cancer vaccine (personalized)-Cancer (general/personalized per patient)
02
Targets
Patient-specific tumor neoantigen-HLA complex
Beyond the preview
Go deeper on Renhaim personalized neoantigen cancer vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Renhaim personalized neoantigen cancer vaccine.